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ABSTRACT
Bariatric Surgery Versus Lifestyle Interventions
In Managing Obesity In Patients With Type II
Diabetes: A Systematic Review
Leslie C Nakaya
College of Nursing
Masters of Science
Purpose: Obesity, with coexisting T2DM, is difficult to treat successfully for various reasons and
carries enormous health risks and financial burdens. The purpose of this systematic review is to
compare outcomes of conventional medical treatment to bariatric surgery for the treatment of
T2DM, and determine which patients may be appropriate for referral.
Data Sources: An electronic search of the literature was conducted to identify studies from 2008 to
2014 in the following databases: CINAHL, National Library of Medicine PubMed®/MEDLINE®,
EBSCO, SciVerse®, Springer Link®, and the Cochrane library.
Conclusions: Bariatric surgical options, even before weight loss occurs, positively affect glucose
homeostasis and in some bariatric procedures and individuals with particular characteristics,
produce considerable weight loss and remission of diabetes. Positive correlates were younger age,
shorter disease duration, and BMI >30 kg/m2. Secondary outcomes are also improved. The same
effects are seldom realized through conservative methods.
Results/Implications for Practice: All obese patients should be referred for intensive intervention,
with the minimum goal of 10% weight loss. Under certain circumstances, referral for bariatric
surgery should be considered, particularly for individuals with BMI >40 kg/m2, or BMI ≥35
kg/m2 and at least one obesity related co-morbidity. Others may be considered on a case-by-case
basis.

Keywords: Type 2 Diabetes Mellitus, Bariatric Surgery, Lifestyle Intervention, Obesity,
Systematic Review
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Introduction
In the United States, more than one-third of the population is obese, defined as a BMI
>30 kg/m2, with an increasing number reaching severe obesity (BMI >40 kg/m2) (Centers for
Disease Control and Prevention, 2012). A similar trend is occurring worldwide, particularly in
urban areas and developing countries (Beaubien, 2014; Mathers & Loncar, 2006). There is an
undisputable link between obesity and the development of chronic diseases, including type 2
diabetes mellitus (T2DM).
Obesity, with coexisting T2DM, is difficult to treat successfully for various reasons and
carries enormous health risks and financial burdens. Sustained hyperglycemia is a risk factor for
micro and macro vascular disease, including neuropathy, nephropathy, and retinopathy, and is a
significant contributor to cardiovascular disease (Jeong & King, 2011; Paneni, Beckman,
Creager, & Cosentino, 2013). It is estimated that the cost of care for obese individuals with
diabetes is two to four times more expensive than their non-diabetic counterparts (Klein, Ghosh,
Cremieux, Eapen, & McGavock, 2011). The American Diabetes Association (2013) reports the
cost of diabetes, disease related complications, and lost productivity surged to more than $245
billion per year in 2012, an increase of 41% from 2007 estimates, and current projections
indicate that prevalence and associated costs will continue to increase.
The relationship between weight loss and the amelioration of T2DM is not well
understood, or if such a relationship exists. Numerous data suggest that even modest weight loss
may be beneficial in reducing diabetes risk factors. Attaining weight loss through conservative
measures, such as diet and exercise, is generally recommended first. Yet studies that compared
conservative measures with surgical interventions demonstrate superior and more durable
outcomes favoring bariatric surgery. Bariatric surgery, independent of weight loss, seems to
drastically halt the progressive effects of diabetes. Hage and colleagues (2012) suggest that
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bariatric procedures may alter the release of adapokines and gut peptide hormones such as
ghrelin and glucagonlike peptide-1 (GLP-1), which may account for improvements that are
observed just days postoperatively, before significant weight loss has occurred.
Primary care providers, including nurse practitioners, are responsible for 80-90% of the
surveillance and management of patients with diabetes (Morrison, Shubina, Goldber & Turchin
2012; Unger, 2012). This provides an opportunity for evaluation, aggressive management to
avoid complications, and referral for T2DM complications when necessary. When non-surgical
conservative measures such as diet, exercise, and pharmacotherapies are unsuccessful in the
treatment of obesity related T2DM, the International Diabetes Federation recommends the
consideration of evidenced based surgical interventions (Dixon, Zimmet, Alberti, Mbanya, &
Rubino, 2011)
Despite numerous studies and trials verifying the efficacy and safety of bariatric surgery
to treat T2DM, both practitioners and patients remain reluctant to consider surgery other than as
a “last resort.” (Dixon et al., 2011; Sarwer et al., 2012a; Sarwer et al., 2012b). The purpose of
this systematic review is to compare outcomes of conventional medical treatment to bariatric
surgery for the treatment of T2DM, and determine which patients may be appropriate for
referral. Clinical implications will also be identified.
Methods
An electronic search of the literature was conducted to identify studies from 2008 to 2014
in the following databases: CINAHL, National Library of Medicine PubMed®/MEDLINE®,
EBSCO, SciVerse®, Springer Link®, and the Cochrane library. Search terms included obesity,
gastric bypass, bariatric surgery, Roux-en-Y, sleeve gastrectomy, laparoscopic adjustable gastric
band, medical, conservative, treatment, management, and diabetes mellitus. Limits were set to
identify peer reviewed research studies in the English language. The initial database search
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identified 371 articles for review. Duplicates, case studies, commentary, dissertations, consensus
statements, and letters to the editor were excluded.
To be included, research was based on adult participants medically diagnosed with
T2DM for any length of time prior to interventions and those patients comprising a significant
proportion of the study population. Diabetes improvement after intervention was a primary end
point of the study’s purpose. Abstracts were scanned for suitability and references searched to
identify other potential articles for inclusion. Studies were excluded if total participants
numbered fewer than fifteen, if the focus was diabetes prevention or predicting surgical
outcomes, prenatal or postpartum patient outcomes, or included pediatric patients. 312 studies
were excluded based on the criteria, leaving twenty-one for more thorough review. A detailed
assessment of the literature and cross-referencing of articles suggested three for inclusion.
Ultimately, two were excluded leaving twenty-two studies that met the criteria for inclusion (See
figure 1).
Due to the various study designs included, quality of the studies was assessed using the
methodology described by Whittemore and Knafl (2005). Each study was coded on a 2-point
scale, high or low, relative to two criteria pertinent to this review, methodological rigor and
relevance of the data. Data relevance was rated high in all included studies, and methodological
rigor in most. Identified limitations are presented in the discussion section.
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Figure 1. Article Identification, Screening, and Selection Process.
Initial Database Search Results
(n= 371)
Several databases, January 2008-December 2014 English
peer reviewed studies using various search terms including:
“Gastric bypass, Bariatric surgery, diabetes, T2DM,
conventional or medical therapy”

-‐
-‐
-‐
Screening title, abstract
(n= 333)

	
  

-‐
-‐
-‐
-‐

Detailed assessment of the
literature text with subsequent
cross-referencing
(n=21)

Excluded (n= 38)
Case Studies, letters to the editor,
commentary, dissertations, consensus
statements, CEU’s
Non-English language
Duplicate removal

Excluded (n= 312)
Pediatric or pregnant patients, animal
studies
≤ 15 total patients in the study or 9 in
any one treatment arm
Patients with T2DM were not a
significant proportion of the study
Improvement in T2DM was not a
primary end point of the study purpose

	
  

-‐
-‐

Excluded (n= 2)
Study of stand-alone newer procedure,
less studied
Insufficient data to contribute to review
Included (n=3)

	
  
Studies included for systematic
review (n=22)

Results
Study Characteristics
A total of 22 studies were evaluated. Nine were prospective studies, either cohort or
comparative in nature, including one randomized control trial (RCT) (Kashyap et al., 2013).
Seven were retrospective studies generally conducted as chart reviews, with one being a large
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cohort study (Arteburn, et al., 2013), and seven were RCTs, though only two were double
blinded (Dunn et al., 2012; Lee et al., 2011). It would have been optimal to include more
randomized double blind studies, however, the potential surgical intervention seldom permitted
for this type of study design.
Data was published for 7,297 people who participated in the twenty-two studies; the
smallest group consisted of 18 participants (Abbatini et al., 2012) and the largest evaluated 4,434
participants (Arteburn et al., 2013). Studies were conducted in the United States, Australia, Asia,
Brazil, Chile, Italy, and Taiwan. Study duration and subsequent follow up time varied greatly,
the shortest being one month in two studies (Dunn et al., 2012; Plum et al., 2011), and the
longest 5-6 years in four studies (Adams, et al., 2012; Arteburn et al., 2013; Brethauer, Aminian,
Romero-Talamas, Batayyah & Mackey, 2013; Lakdawala et al., 2013). The average duration of
follow up was 12-24 months. The relative brevity of follow-up limits the ability to project
longer-term outcomes such as weight regain and disease reoccurrence. Additional well-designed
longitudinal studies may better define outcome durability.
Patient Characteristics
Study participants were between the ages of 18-72, with the mean age between 45-50.
Overall, a greater number of participants were women, from 39% (Cohen et al., 2012) to 88%
(Dunn et al., 2012), though gender varied between studies. Body mass index (BMI) was
reported as either a range or a mean, or both. Six studies included participants with a BMI
between 30-35 kg/m2, two studies 30-40 kg/m2, and four studies a BMI > 35 kg/m2. Three
studies in Asia specifically investigated intervention impacts on patients with lower BMI’s (2535 kg/m2) (Huang et al., 2011; Lee et al., 2011; & Lee et al., 2012). One study (Brethauer et al.,
2013) only included patients with a BMI over 40 kg/m2. The remainder of the studies reported a
BMI range between 27-72.1 kg/m2, with an overall mean of 37.8 kg/m2. One study did not have
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BMI data available for all participants and excluded BMI from the reported data (Arteburn et al.,
2013). HbA1c, used as a biochemical measure of glycemic control and diagnostic tool for
T2DM, was reported inconsistently. Only fifteen studies reported pre-intervention HbA1c, with
a mean of 8.6%, and all but five studies reported the duration of diabetes. Average disease
duration ranged from six months to 20 years, with an average mean of 8.9 years. Several studies
considered intervention effects on individuals with disease duration less than five years, and one
study duration less than two years (Dixon et al., 2008).
Intervention and Definitions
Of the 7,297 study participants, 1106 comprised the non-surgical control groups. 368
were part of conservative management groups, defined by any intervention that included dietary
changes, exercise, pharmaceutical therapy, and counseling. The remaining 738 were free to
pursue interventions independently, but did not receive an intervention as part of the study. The
conservative management groups were described in numerous ways including routine medical
management, intensive medical therapy, low calorie diets, or lifestyle changes. Surgical
interventions included 104 patients who had laparoscopic adjustable gastric banding (LAGB), 27
had a duodenal switch (DS), and 20 had a biliopancreatic diversion (BPD). 5,884 had Roux-enY gastric bypass (RYGB) surgery, either open or laparoscopic, some in conjunction with
lifestyle interventions; 20 of those also had an oomentectomy, and 30 had duodenum exclusion
as a part of the surgical intervention. 156 patients had a sleeve gastrectomy (SG), generally
laparoscopically, 30 with concurrent duodenum exclusion and 20 with concurrent lifestyle
intervention. Forty obese, non-diabetic patients were included as a part of matched control
groups for two studies; they are included in the above figures though not implicated in the
outcomes or discussion.
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Outcomes
Weight loss. All but one study addressed weight loss in some form, either total
percentage lost, amount lost in kilograms, BMI changes, excess weight loss percentages, or waist
circumference. Two studies had very brief follow up periods and primary end points related to
changes in incretin and hormone production affecting glycemic control, and specific statistics
regarding weight changes were not provided (Laferrere, et al., 2011; Plum et al., 2011). In the
remainder, without exception, individuals in surgical intervention groups achieved greater weight
loss than those in conventional treatment groups, although the outcomes varied between
interventions. The greatest weight loss occurred in the groups having RYGB, BPD, or DS
procedures. In two separate studies, BPD and DS were each compared with RYGB and no
statistically significant difference was noted, however there were far more RYGB patients
represented in this review (Dorman et al., 2012; Mingrone et al., 2012). Sleeve gastrectomy
procedures produced the next greatest weight loss, followed by laparoscopic adjustable banding
procedures. One study noted similar weight loss between two surgical groups, RYGB and SG (p
=0.58), but observed a significant difference in reduced truncal fat in the RYGB group at twentyfour months (-16% vs. -10%, p =0.04) (Kashyap et al., 2013). In addition, greater improvements
in A1c and beta cell function were noted, suggesting that decreased truncal fat may predict better
outcomes.
Adams and associates (2012) and Brethauer and associates (2013), two of the longer term
studies, documented durable weight loss of 27.7 ± 1.2% and 28.1±10.9% respectively at five or
more years in RYGB groups. Brethauer et al. also included SG and LAGB treatment arms that
experienced weight loss of 22.2 ± 9.3% and 13.2 ± 10.7%, respectively, at five or more years.
Among the conventional treatment groups, weight loss varied from 0-7.9% at one and two years
(Abbatini et al, 2012; Dixon et al, 2008; Dorman et al., 2012; Ikramuddin et al., 2013; Kashyap
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et al., 2013; Leslie et al., 2012; Mingrone et al., 2012; Schauer et al., 2012), and 0-0.2% weight
gain at six years (Adams et al., 2012).
HbA1c. HbA1c (A1c) has become a standard diagnostic and monitoring tool for T2DM,
along with fasting plasma glucose (FPG) and oral glucose tolerance testing (OGTT). Bonora and
Tuomilehto (2011) report A1c testing has several advantages over FPG or OGTT including the
ability to better chronicle chronic hyperglycemia, eliminate the need to fast, immune to outside
stressors, and increase association with chronic complications. Diabetes remission, or resolution,
is often a determinate of intervention success, yet may be subjective based on the goal study
parameters. The 2013 American Diabetes Association (ADA) guidelines recommend
maintaining A1c below 7% and fasting plasma glucose (FPG) ≤ 126 mg/dL in persons with
T2DM to reduce vascular disease. T2DM is diagnosed in part after an A1c ≥ 6.5%, with A1c
parameters for prediabetes established as 5.7-6.4%.
There was variance from study to study regarding desired A1c levels, with some authors
subscribing to more stringent guidelines while others more liberal. Conservative, or non-surgical
treatment for T2DM, was a part of thirteen studies. Seven studies reported no measurable
change in glycemic control as monitored by A1c or FBG. The remainder described an average
remission rate of 9% (range 5.9-13%), including one study that described remission rates of 6%
and 8% from two non-surgical control groups that persisted at the six year follow up (Adams et
al., 2012).
In the surgical treatment arms, two studies did not report specific outcomes relative to
A1c or FPG (Laferrere et al., 2011; Plum et al., 2011). Four studies reported A1c goals of 7%
per the ADA guidelines, each considering glycemic control as a part of a triple endpoint for
patients with metabolic syndrome.	
  	
  In the studies, an A1c <7% is not identified as resolved
diabetes, but improved glycemic control. Nine studies considered an A1c of <6.5% as a

9

remission point, while others adopted more stringent guidelines of <6.2% (Dixon et al., 2008),
and <6.0% in the remaining eight studies.
The SG procedure was included as a part of six studies involving 156 patients, which
reported remission rates of 46.7% (range 26-89%) at one year. Two studies had secondary
analysis points at two and five years, indicating relapse rates of 15.8% and 17% respectively
among those who had initially remitted. (Brethauer et al., 2013; Kashyap et al., 2013). Each of
those studies defined remission as an A1c < 6.0%, indicating that patients who relapsed
continued to have improved glycemic control relative to baseline values and were considered
partial remitters. LAGB was performed in 96 diabetic patients and an average remission
occurrence of 25% (range 0-50%) was reported at one to two years. Interestingly, Dorman and
associates (2012) had the most liberal A1c requirements, but reported no significant change
among LAGB patients at twelve months.
Twenty studies included RYGB procedures, alone or in conjunction with other
interventions. All twenty reported considerable improvements in glycemic control among
RYGB patients, including A1c and when reported, FPG. Of the eighteen studies that considered
A1c as a marker for diabetes resolution, remission was reported in an average of 61.2% (range
27-93%) of patients at the first, or final end point. A1c improved markedly in RYGB, BPD, and
DS, but when compared, BPD and DS achieved results superior to RYGB (p =0.001 and p <
0.001, respectively) and diabetes was deemed resolved in more patients (95% at two years for
BPD, and 81.5% at 12 months for DS). Four studies with multiple analysis points reported
diabetes reoccurrence among 13-35.1% of RYGB patients who had initially remitted.
Insulin sensitivity and beta cell function. T2DM is characterized by cellular resistance
to insulin and impaired insulin secretion leading to sustained hyperglycemia, glucose toxicity,
and eventual destruction of pancreatic beta cells. Twelve studies attempted to measure, in some
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way, the intervention effects on insulin resistance and beta cell function. None of the studies
found significant improvement of insulin resistance, glucose tolerance, or beta cell function in
conservatively treated populations when compared to surgical intervention groups.
Hyperinsulinemic-euglycemic clamps are considered the gold standard in evaluating
insulin sensitivity, however this method is inconvenient, more costly, and time-consuming.
Dunn and associates (2012), used this technique to evaluate diabetic patients following RYGB,
with or without oomentectomy, and discovered that hepatic insulin sensitivity had improved at
one month but muscle insulin sensitivity had not. In the same study, a lower preoperative
hepatic glucose production (HGP) and hepatic insulin sensitivity index (HISI) were positively
correlated to patients with early diabetes resolution when compared to patients who did not
achieve remission.
Serum insulin and HOMA-IR were often used as measures of insulin resistance,
occasionally in conjunction with fasting C-peptide. Eight studies used a combination of the three
measures and found significant improvements in glucose tolerance and insulin resistance in both
RYGB and SG populations alone and when compared to conventionally treated patients. In two
studies, the results endured at the six-year analyses points (Adams et al., 2012; Cohen et al.,
2012). Lee and associates (2011), found no significant difference in either fasting serum insulin
or HOMA-IR twelve months after patients were surgically treated with RYGB or SG.
C-peptide levels were associated with likelihood of diabetes remission, as alternative
markers of beta cell function, according to Lakdawala et al. (2013). Results from the study
suggest that C-peptide levels >6 mg/dL were associated with 100% remission, while C-peptide
between 3-6 and 1-3 were associated with remission rates of 75.8% and 31%, respectively.
Kashyap and associates (2013) indicated that RYGB patients had near-normal glucose tolerance
and a 5.8 fold increase in pancreatic beta cell function at one to two years. The phenomenon was
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not observed to the same degree in SG patients who were a part of the same study, despite
comparable weight loss. Plum et al. (2011) reported improvements in the disposition index (DI),
including measurements such as insulin sensitivity (SI) and HOMA-IR, in RYGB patients
compared to a low calorie diet (LCD) group after comparable weight loss. Additionally, the
acute insulin response to glucose (AIRG) was improved in both LCD (p =0.04) and RYGB (p
=0.03), however overall SI and DI improvement was significantly greater in RYGB patients (p
=0.02 and p =0.04 respectively).
Secondary outcomes. The International Diabetes Federations (IDF) consensus
worldwide definition of metabolic syndrome (2006) has identified a cluster of risk factors that
contribute to an increased risk of heart disease, specifically diabetes or prediabetes, abdominal
obesity, abnormal cholesterol, and increased blood pressure. Numerous studies in this review
considered secondary outcome measures of one or more of these risk factors post-intervention,
including triglycerides, high-density lipoprotein (HDL), and blood pressure.
Ten studies reported decreased triglycerides post-intervention, with the most significant
improvement in RYGB and BPD compared to conventional treatment, though there was some
conflict among reports. Mingrone et al. (2012) indicated significant improvement in BPD
patients compared to both RYGB and conventional treatment, which also improved, but not
significantly from one another. Schauer and associates (2012) reported significant decreased
triglycerides in RYGB and SG treatment groups compared to conventional therapy, with no
significant difference from one another. However, Kashyap (2013) compared RYGB to SG and
conventional groups and found an average decrease of 32.44 points with no significant difference
between the three groups. Dixon et al. (2008) reported significant change in LAGB patients
compared to conventional therapy (-69.6, 95 % CI: 125.3-13.6, p =. 02).
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Changes in HDL were reported in eleven studies and results varied widely. Adams and
colleagues reported an increase of 13.1 points and significant improvement between RYGB and
two conventional groups at six years, while Serrot et al. (2011) appreciated no significant change
at one year between RYGB group and conventionally treated patients. Three studies noted
significant improvements in HDL in the surgical groups, either alone, or when compared to
conservative treatment, however the results did not differ significantly between the surgical
interventions (Kashyap et al., 2013 Lee et al., 2011; Schauer et al., 2012). One study found that
33% of patients previously requiring medication therapy for dyslipidemia were able to
discontinue therapy before the one year follow up (Lakdawala, 2013). At five years, that number
had dwindled to 13%, with 20% having resumed dyslipidemia medication.
Thirteen studies related alterations in blood pressure, with generally modest decreases
seen. One study reported no significant change (Dixon et al., 2008) and four studies reported
significant improvement with no remarkable differences between surgical versus conventional
treatment groups (Lee et al., 2011; Lee et al., 2012; Mingrone et al., 2012; Schauer et al., 2012).
Two studies reported significant improvements in RYGB groups when compared to three
separate conventional groups (p < .001, p < 0.01, and p < 0.01 respectively) (Adams et al., 2012;
Leslie et al., 2012). In spite of improvements in secondary measures, medication therapy was
still recommended in many patients. Interestingly, two studies mentioned inappropriate
discontinuation of medication therapy (17%-41%) for hypertension and dyslipidemia or both, at
the one or two year analysis points. (Leslie et al., 2012; Serrot et al., 2012)
Complications. In 2009, researchers for the Agency for Healthcare Research and
Quality (AHRQ) released a study of more than 9,500 patients at 652 facilities who underwent
bariatric surgery between 2001-2006 (Encinosa, Bernard, Du, & Steiner, 2009). Results
indicated a reduction in postoperative complications during the first six months, from 42% to
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33% at the conclusion of the study. In addition, post-operative infection rates had decreased by
58%. During this same time period, the incidence of bariatric procedures increased by 113% and
included many older and sicker patients. Much of the improvement has been attributed to
standardization of procedures including a significant increase in laparoscopic procedures, which
increased by 62%, and specialized surgical centers that often include multidisciplinary teams.
Several of the studies in this review occurred during the same time period as the AHRQ
study, as techniques and processes were evolving. Thirteen studies addressed complication rates
and types, with an overall complication rate of 16.6% (range 3.8-40.7%) in the surgical
population. Complications were categorized as major or minor, and early or late, and included
risks inherent to surgery such as wound infections, deep vein thrombosis, and pulmonary events,
as well as complications unique to gastrointestinal surgery such as anastomotic leaks, stenosis,
strictures, bowel obstruction, intrabdominal bleeding, and incisional hernias. Other adverse
effects included nausea and vomiting, cholecystitis, gout attacks, and dumping syndrome.
Nutritional deficiencies have been reported as a common postoperative effect and vitamin
supplementation after surgery is anticipated, particularly with procedures that exclude more of
the stomach, duodenum, and ileum. Only one study mentioned nutrient deficiencies, most
commonly in the surgical population, including iron or vitamin B deficiencies,
hypoalbuminemia, or low Vitamin D (Ikramuddin et al., 2013). In the conventional treatment
arm there was a 12.9% (range 9-26.6%) incidence of adverse events reported in four studies.
The events were generally related to medication or meal substitution intolerances that resolved
with discontinuation, or as a result of admissions for co-morbidities such as chest pain,
hypoglycemia, or arrhythmias.
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Discussion
Twenty-two studies met the criteria for inclusion in this review, resulting in systematic
analyses to determine the efficacy of lifestyle interventions compared to bariatric surgery
methods in treating obese patients with T2DM. Several factors were examined, including weight
loss, HbA1c, insulin resistance and beta cell function, secondary outcomes, and complication
rates. Some comparisons were also made between bariatric surgery types. In all the studies that
measured weight outcomes, results were superior in surgical groups compared to conservatively
treated groups. Weight loss, even if modest, is associated with improvement or elimination of
metabolic syndrome and a decrease in cardiovascular risk factors (Heffron et al., 2013; Morton,
Crowe, Leva, & Garg, 2013; Sjostrom et al., 2007). Seldom is the weight loss achieved through
non-surgical measures sufficient to realize these benefits, particularly in extreme obesity. In this
review, most studies identified a correlation between weight loss and improvement in diabetes
measures, but not all. Cohen et al. (2012) stated that no correlation between weight loss and
reductions in A1c occurred at any time point, and occurred between weight loss and FPG only at
five and six years.
Biochemical measures of glycemic control and pancreatic beta cell function improved
most in more aggressive restrictive/malabsorptive surgical procedures that altered the digestive
tract, such as RYGB, BPD, and DS. In some cases, the endoluminal sleeve or SG, generated
results that were similar or slightly less efficacious, and may be an appropriate surgical option
for patients with a lower BMI or fewer co-morbidities. LAGB, or gastric banding, is a reversible
procedure that resulted in modestly improved HbA1c in one study (Dixon et al., 2008) and no
real improvement in another (Dorman et al., 2012). Several predictors of successful diabetes
resolution emerged in four studies (Arteburn et al., 2012; Huang et al., 2011; Lakdawala et al.,
2013; Lee et al., 2012). Positive correlations included disease duration <5-7 years, younger age,
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higher BMI (> 30 kg/m2) or percentage of EWL, and increased fasting C-peptide levels,
specifically >6 mg/dL. These findings suggest that earlier recognition of candidates and referral
for intervention is needed.
It is difficult to compare the risks of surgical intervention with the benefits of both weight
loss and improved glycemic control. Though risks exist and the research demonstrates the
potential for weight regain and a degree of diabetes relapse, we should consider the years of
improved glycemic control and secondary effects following bariatric surgery and the impact on
future health and reduced microvascular disease. Sjostrom et al. (2007), in referencing the
observations from the Swedish Obesity Study (SOS), a prospective controlled cohort study
involving 4047 obese subjects comparing bariatric surgery subjects (n=2010) with matched
controls (n=2037), suggests that overall mortality was decreased in previously obese surgical
subjects when compared to the controls after almost eleven years of follow up. At 10.9 years,
mortality was 5.0% in the surgical group compared to 6.3% in the control group (95% CI: 0.590.99, p =0.04). The most common causes of death were related to myocardial infarction, nearly
double in the control group versus the surgery group, and cancer, where incidence was one-third
greater in the control group.
Limitations
Our systematic literature review identified several limitations in the research to date.
First, most of the results were drawn from retrospective and prospective cohort studies with
limited length of study, small population samples, and unequal or absent comparative groups.
Additional well-designed randomized studies, particularly longitudinal studies, would verify or
dispute existing literature and help define which populations would benefit from surgical
intervention, specifically cost versus benefit in individuals with a lower BMI. Additionally, the
risks and benefits of various surgical procedures may be further defined. Secondly, T2DM
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diagnosis and remission criteria and measures of glycemic control and pancreatic function vary
widely between studies. Standardized evaluation, remission criteria, and reporting methods in
future studies would greatly enhance the existing evidence base and permit sounder clinical
decision-making.
Finally, the majority of the research seems to be founded and conducted in surgical
centers by surgical staff and may include some bias towards surgical intervention. Several
studies included conventional treatment arms with no specific interventions, serving only as
matched comparison groups. Other studies vaguely described conservative interventions; few
included intensive conservative measures equal to those of surgical intervention. To avoid
scientific bias, more studies should include truly intensive multi-component interventions
including possible inpatient therapy, psychological evaluation and counseling, and consistent
outpatient follow up and dietary counseling.
Conclusion
Obesity and T2DM are increasing in prevalence and a leading cause of morbidity and
mortality in the United States. Unfortunately, conservative methods have proven ineffective in
generating consistent and sustainable weight loss outcomes and diabetes regression in morbidly
obese individuals with T2DM. Research regarding patients with BMI 30-35 kg/m2, or Class I
Obesity, and T2DM appears promising but currently lacks sufficient evidence to recommend
unequivocal surgical referral.
PCP’s, as gatekeepers, should recommend all obese patients engage in an intensive,
multi-component intervention with the minimum goal of 10% weight loss. For patients who
have participated in one or more intensive programs for a minimum of six months and been
unsuccessful, referral for surgical consult should be considered in those with a BMI >40 mg/k2,
or BMI ≥35 mg/k2 and at least one obesity related co-morbidity. Patients with BMI ≥30 kg/m2,
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T2DM, and at least one obesity related co-morbidity should be managed aggressively and
surgical referral carefully considered. More invasive and aggressive surgery methods, like the
RYGB, BPD, and DS, are generally reserved for patients with a higher BMI and more comorbidities, however, early research suggests that patients with Class I obesity and any comorbidity, particularly diabetes, may benefit from earlier intervention. The gastric sleeve, an
emerging procedure with results nearly equivalent to more invasive procedures, may also be an
option.
We recommend further research to elucidate the mechanisms of diabetes improvement
following bariatric surgery. Additional understanding and validation of surgical effects may help
overcome reluctance among providers and patients to consider bariatric surgery options when
conservative methods have not produced meaningful clinical results. In the meantime, PCP’s
should evaluate patients on an individual basis, considering cost and weighting complications
associated with surgery against those associated with uncontrolled T2DM, and utilize available
behavioral, medical, psychological, and as determined, surgical interventions in managing obese
patients with T2DM.
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Table 1. Study Characteristics and Outcomes.

Study

Abbatini et
al.
(2012)
Italy

Study Design

BMI

Intervention

Prospective

30-35

LSG (n=9)
CMT,
undefined (n=9)

Diabetes
Remission
Criteria –
A1c
<6.5%

Outcomes

Analysis
Points

Significant weight loss in LSG
1, 3, 6,
group (p<.05), measured by BMI, 9, 12
as well as decrease in A1c (p<.05) mo.
and FPG (p<.05). Diabetes
resolved in 8/9 patients. No
significant changes in CMT
group.

Adams et al.
(2012)
USA

Prospective

≥ 35

RYGB (n=418)
NSC 1 (n= 417)
NSC 2 (n=321)

<6.5%

RYGB group maintained 27.7%
weight loss at 6 years,
decreased from 34.9% at 2
years. NSC 1 weight gain 0.2%
at year 6, and NSC 2
unchanged. Diabetes remission
in RYGB patients 75% at year
2, decreasing to 62% (95% CI,
49-75%) at year 6 vs 8% NSC 1
(p<.001), and 6% NSC 2
(p<.001

2 years
6 years

Arteburn et
al.
(2013)
USA

Retrospective
Cohort

NR

RYGB, open
(n=2461)
LRYGB
(n=1973)

<6.0%

No data regarding weight loss.
68.2% (95% CI, 66-70%)
diabetes remission within 5
years. 35.1% of those
redeveloped diabetes within 5
years. Median duration
remission 8.3 years.

Mean
3.1 years

Brethauer et
al.
(2013)
USA

Retrospective
Cohort

>40

RYGB (n=162)
LSG (n=23)
LAGB (n= 32)

<6.0%

Mean EWL 55% at 5+ years.
RYGB EWL 11% higher than
LSG (p=0.047) and 20%
higher for LSG than for LAGB
(p=0.004). 24% cohort
achieved diabetes remission at
5 years, 26% partial remission
(A1c 6-6.4%). Results best in
RYGB vs LSG (p<.006),
RYGB vs LAGB (p<0.001),
and LSG vs LAGB (p=0.04).
27% of RYGB group who
achieved complete remission
maintained at 5 years. Among
participants that initially
remitted (n=127), there was a
19% relapse rate at 5 years for
entire cohort.

2 years,
5+ years

Boza et al.
(2011)
Chile

Retrospective

30.435

LRYGB (n=30)

<6.5%

At 2 years, average BMI 23.9
±2.4 kg/m2, representing a
28.4% decrease (p<0.001). At
12 mo., 83.3% patients
achieved remission of

12 mo.
2 years
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Study

Study Design

BMI

Intervention

Diabetes
Remission
Criteria –
A1c

Outcomes

Analysis
Points

diabetes, decreasing to 65% at
year 2. Ten patients with
early or late complications,
most often gastro-jejunal
stenosis in 23.3% (13.3%
early, 10.0% late) and one
incidence of early pulmonary
atelectasis.
Cohen et al.
(2012)
Brazil

Prospective

3034.9

RYGB (n=66)

<6.5%

Significant decreases in total
body weight and waist
circumference (p<0.001).
HbA1c and FPG decreased
significantly (p<0.001 for
both), seen primarily in the
first 6 months. Remission of
diabetes occurred in 88% of
patients with no reoccurrence
during follow up (100%
retention). No correlation
between weight loss and
HbA1c at any point, and
correlation between weight
loss and FPG only at 5 and 6
years (p=0.001 and 0.017
respectively). Minor
complication rate of 15% (not
requiring reoperation), no
major morbidity or mortality.

7, 30, 90
days
6, 12
mo.
2, 4, 5, 6
years

Dixon et al.
(2008)
Australia

RCT
nonblinded

30-40

LAGB (n=30)
CMT (n=30)

<6.2%

LAGB group achieved mean
20% weight loss at 2 years,
compared to mean 1.4% loss in
CMT group (p<.001). 43% of
LAGB group and 13% of CMT
group achieved remission at 2
years (p<.001). HbA1c and
FPG were significantly
improved at 2 years in LAGB
group (p<.001 for both) and
positively correlated with
greater percentage of weight
loss. 13% adverse effects first
year in LAGB, 26.6% adverse
effects in conventionally treated
group.

2 years

Dorman et
al.
(2012)
USA

Retrospective

>35

DS (n=27)
LAGB (n=30)
RYGB (n=86)
NSC (n=29)

<6.5%

Both DS and RYGB patients
experienced substantial weight
loss over one year, though the
difference was not statistically
significant. HbA1c was also
markedly decreased, though
1.2% less in DS patients than

1 week,
1, 3, 6,
9, and 12
mo.
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Study

Study Design

BMI

Intervention

Diabetes
Remission
Criteria –
A1c

Outcomes

Analysis
Points

RYGB (p=0.001). LAGB
patients lost even less weight
than RYGB, and had an average
8.9 kg/m2 higher BMI than
case-matched RYGB patients
post-intervention. LAGB
patients HbA1c did not change.
No significant change in weight
or HbA1c was seen in NSC
group. Diabetes was considered
resolved at one year in 81.5% of
DS patients, 58.1% of RYGB
patients, 20% of LAGB
patients, and 3.4% of NSC
patients.
Dunn et al.
(2012)
USA

RCT
Double blinded

48
(mean)

RYGB (n=20)
RYGB with
oomentectomy
(n=20)

<6.5%

Both groups lost considerable
weight at one month, with no
clear effect of additional
oomentectomy on weight loss or
insulin sensitivity. Of the 17
participants with diabetes, 59%
were considered remitted at 1
month. Those with diabetes had
a higher baseline hepatic
glucose production (HGP) than
those without (p=0.003), which
improved to a greater extent
after RYGB (p=0.006). At 1
month, overall hepatic insulin
sensitivity improved but skeletal
muscle insulin sensitivity did
not.

1 mo.

Huang et al.
(2011)
Taiwan

Prospective

25-35

LRYGB (n=22)

<6.0%

Significant weight loss,
decreased mean BMI from 30.8
± 2.9 preoperatively to 23.7±1.6
by 12 months (p<0.001). At 12
months, 63.6% achieved
remission of T2DM, 27.3%
glycemic control (A1c < 7%
with no diabetic medications),
and 9.1% had improved.
Positive correlation between
those who remitted and younger
age (p=0.002), higher BMI
(p=0.001), and shorter disease
duration (p=0.001). No major
morbidity or mortality, minor
complications within first year
9%.

12 mo.

Ikramuddin
et al.

RCT
nonblinded

3039.9

LRYGB +
Lifestyle (n=60)

<7.0%
&

At 1 year, LRYGB participants
lost 26.1% total body weight

12 mo.
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Study

Study Design

BMI

(2013)
USA/Taiwan

Kashyap et
al.
(2013)
USA

Intervention

LMM (n=60)

Prospective
RCT

36.1
(mean)

IMT (n=20)
RYGB / IMT
(n=20)
VSG / IMT
(n=20)

Lakdawala et Prospective
al.
(2013)
India

30-35

LRYGB (n=52)

Diabetes
Remission
Criteria –
A1c
<6.0%

Outcomes

Analysis
Points

compared to 7.9% in the LMM
group. In addition, 49% of
LRYGB achieved the triple
endpoint (A1c<7%, LDL<100
mg/dL, and SBP< 130 mm Hg)
and 44% had a A1c<6.0%. In
the LMM group, the triple
endpoint and A1c<6% were
only realized 19% and 9%,
respectively. 36% total
complication rate in RYGB
group, thought only 20% of
those were GI related, including
4 early serious postoperative
complications, and 5 late
postoperative. LMM group
25% adverse events, though
only 6% directly GI related.

<6.0%

Greatest weight loss in the
RYGB group, though the VSG
group statistically similar at 24
months (p=0.30), however
truncal fat reduction was
significantly greater in RYGB
than VSG group (p=0.006).
A1c reduced most in RYGB
group at 12 mo. vs VSG
(p=0.25) and IMT (p=0.02). At
24 months, 33.3% of RYGB
had diabetes remission vs
10.5% of VSG (p=0.12) and
5.9% of IMT (p=0.09). A 5.8
increase in B-cell function was
noted from baseline in RYGB
group, with only negligible
changes in IMT and VSG
groups. Leptin decreased most
significantly compared to IMT
(p<0.001) and VSG (p=0.01).
Complications included
reoperation on 3 persons from
surgical group, no morbidity.

<7%

Median EWL of 72.2% (6692%) at one year, and 8/52
patients had weight regain
leading to %EWL of 67.% (4888%) at 5 the end of 5 years.
At 1 year, 73.1% achieved
remission for T2DM, 23.1%
partial remission, and 3.8
unchanged. At 5 years, 15.4%
who remitted initially relapsed

12, 24
mo.

12 mo.,
5 years
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Study

Study Design

BMI

Intervention

Diabetes
Remission
Criteria –
A1c

Outcomes

Analysis
Points

and were considered partially
remitted. Positively correlated
with diabetes remission were
shorter disease duration (<5
years), higher percentage EWL
(>75%), and higher fasting Cpeptide levels (>6 mg/dL 100%
remission, 3-6 mg/dL 75%).
3.8% minor complications in
the early postoperative period
including seromas/nausea. No
late complications, significant
dumping or malnutrition at 1 or
5 years. No mortality.
Laferrere et
al.
(2011)
USA

Prospective

>35

Lee et al.
(2011)
Taiwan

RCT
Double-blind

25-35

RYGB (n=10)
LCD, 10 kg loss
(n=11)

LRYGB +
duodenum
exclusion
(n=30)
VSG (n=30)
without
duodenum
exclusion

NR

RYGB achieved 10 kg weight
loss faster than LCD group
(p=0.003) and FBG and
HOMA-IR decreased similarly,
however, all RYGB patients
were able to discontinue glucose
lowering medications at one
month while only half of LCD
was able to. Glucose tolerance,
measured by OGTT, improved
more in RYGB group than
LCD. Total amino acids
(TAAs) and branched chain
amino acids (BCAAs) decreased
significantly after RYGB.
Lower concentrations of
TAAs/BCAAs are associated
with leaner, non-diabetic
individuals.

1, 2 mo.

<6.5%

At one year, BMI, EWL, and
waist circumference improved
more in the RYGB vs VSG
group as follows (p=.009 BMI,
.06 EWL, and .002 waist
circumference). 70% of
participants achieved remission
T2DM, with greater proportion
of RYGB than VSG (93% vs
47%; p=.02). 10% minor
complication rate, 5% from each
surgical group. No major
complications or mortality.

3, 6, 9,
12 mo.

29

Study

Study Design

Lee et al.
(2012)
Asia

Prospective

BMI

<35

Intervention

RYGB (n=172),
specifically
LRYGB (53)
and LMGBP
(119)

Diabetes
Remission
Criteria –
A1c
<6.0%

LSG (n=24)
LAGB (n=4)

Outcomes

Greatest reductions in BMI and
waist circumference (P=0.027
and 0.002 respectively) seen in
RYGB patients. Remission of
diabetes was realized in 72.4%
patients, highest in RYGB
group vs LSG and LAGB
groups (79.3%, 55.0%, and
50.0%, p=0.062). Disease
duration <5 years, and baseline
BMI >30 kg/m2 correlated with
higher incidence of remission
(p=0.006 and p=0.027). 1%
serious postoperative
complication in RYGB group
and 8% minor complications in
all groups. No mortality.

Leslie et al.
(2012)
USA

Retrospective

40.747.3

RYGB (n=152)
RMM (115)

<7.0%

RYGB group achieved
significant weight loss and had
reduced BMI (p<0.01 for both)
compared to RMM group,
which had no change at 2-year
end-point. 38.2% of RYGB
group and 17.4% RMM group
met triple end point (A1c<7%,
SBP<130 mm Hg, and
LDL<100 mg/dL) at 2 years
(p<0.01), with the most
significant change in HbA1c in
RYGB group vs RMM group,
though medications were still
needed in some patients. 13.8%
of serious complications 90
days postoperatively, 4%
inherent risks of any surgery,
and at least 5% requiring
reoperation. 14.4% readmitted
and 6.3% ED visits with no
admission in first 90 days.
Follow up related to
complications in RMM not
permitted by IRB.

Mingrone et
al.
(2012)
Italy

RCT
nonblinded

>35

RYGB (n=20)
BPD (n=20)
CMT (n=20)

<6.5%

Both RYGB and BPD groups
realized significant weight loss
compared to the CMT group
(p<0.001 for both), though the
difference wasn’t significant
between the two (p=1.00). At 2
years, diabetes remitted for
none of the CMT group,
compared to 75% of the RYGB
and 95% of the BPD groups

Analysis
Points
12 mo.

2 years

2 years

30

Study

Study Design

BMI

Intervention

Diabetes
Remission
Criteria –
A1c

Outcomes

Analysis
Points

(p<0.001 for both comparisons).
Complications included 1 (5%)
minor requiring reoperation at 9
months in BPD group, 1 (5%)
requiring reoperation at 6
months in RYGB, and 2 (10%)
with adverse reactions to
medication in CMT. No
mortality.
Plum et al.
(2011)
USA

Prospective

43-48

RYGB (n=7)
LCD (n=7)

NR

RYGB and LCD groups lost an
equivalent amount of weight in
the specified time period,
though loss occurred in half
the time for RYGB patients.
At second time check, diabetes
medications were discontinued
in all RYGB diabetic patients,
but in none of the LCD group.
Improvements in insulin
sensitivity (Si), HOMA-IR,
and decreases in HDL
cholesterol, Leptin, and
Adiponectin were significant
only in RYGB population (p
=0.002, p <0.01, p <0.05, p
<0.05, and p <0.01
respectively) compared to
LCD patients.

NR,
referred
to 1 mo.

<6.0%

Decreases in weight and BMI
were greater after RYGB than
VSG (p =0.02 and 0.03,
respectively), but both were
significantly greater than those
in the IMT group (p <0.001 for
both comparisons). Glycemic
control improved in all three
groups, with resolution of
T2DM occurring in 42%
RYGB group vs 37% of VSG
group (p =0.008), and 12% of
IMT group (p =0.002) by 1
year. HOMA-IR, HDL, and
CRP improved significantly in
both surgical groups compared
to IMT at 1 year. 22% of
RYGB had complication
within 12 months requiring
hospitalization including 6%
reoperation, 8% of SG
including 2% reoperation, and
9% in IMT group for various
conditions. No mortality.

12 mo.

No diabetes
RYGB (n=9)
LAGB (n=8)

Schauer et
al.
(2012)
USA

RCT
Non-blinded

27-43

RYGB (n=50)
VSG (n=50)
IMT (n=50)

31

Study

Study Design

BMI

Intervention

Serrot et al.
(2011)
USA

Retrospective

3034.9

RYGB (n=17)
NSC (n=17)

Tavares de
Sa et al.
(2011)
Brazil

Retrospective

30-35

RYGB (n=27)

Diabetes
Remission
Criteria –
A1c
<7.0%

<6.0%

Outcomes

Analysis
Points

Weight loss, EWL, and BMI
changes were significantly
greater in RYGB cohort (p
<0.001 for all comparisons),
with only marginal changes in
the NSC group. HbA1c
improved greatly in RYGB
group compared to NSC (p
<.001). No significant
changes were seen in BP or
LDL in either group.
Complications in RYGB
requiring 18% readmission
rate in first year, 2 (12%)
requiring reoperation. Issues
in NSC group not addressed.
No mortality.

12 mo.

Significant changes in BMI and
weight loss (p <0.001 for both)
at 12 months. FPG was reduced
by 46% and HbA1c by 27%.
48% of patients were
considered to have remission of
T2DM, with significant
improvement in 74%. Disease
duration <7 years positively
correlated with better glycemic
control (p =.03).

20 mo.
(mean)

Surgical Procedures referenced, all considered forms of Gastric Bypass Surgery
(“L” before any procedure indicates a laparoscopic approach)
RYGB= Roux-en-Y Gastric Bypass, DS=Duodenal Switch, BPD= Biliopancreatic Diversion SG= Sleeve
Gastrectomy, AGB= Adjustable Gastric Banding,
Non-surgical interventions
NSC= Non-surgical control, LMM=Lifestyle Medical Management Group, CMT = Conventional Medical Therapy,
IMT-Intensive Medical Therapy, RMM= Routine med

